Trial Profile
Phase I/II trial of BPX-701 in patients with PRAME-expressing sarcomas and neuroblastomas
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 17 Mar 2015
Price :
$35
*
At a glance
- Drugs BPX 701 (Primary)
- Indications Neuroblastoma; Sarcoma
- Focus Adverse reactions; First in man
- Sponsors Bellicum Pharmaceuticals
- 17 Mar 2015 New trial record
- 11 Mar 2015 This trial is expected to be initiated by the end of 2015, according to a Bellicum Pharmaceuticals media release.